No Data
No Data
ChemPartner PharmaTech Ties Up With University to Develop Immunotherapy Drugs
Chempartner Pharmatech (300149.SZ): Shanghai Chempartner signed a strategic cooperation framework agreement with the Hong Kong Polytechnic University.
Chempartner Pharmatech (300149.SZ) announced on August 12 that its wholly-owned subsidiary, Shanghai Chempartner Co., Ltd., has recently signed a Strategic Cooperation Framework Agreement with The Hong Kong Polytechnic University (PolyU) to explore collaboration opportunities in the development of novel immunotherapeutic drugs. The collaboration will combine the professional knowledge of the academic and pharmaceutical communities, with a long-term goal of benefiting cancer patients. PolyU will provide new targets and expertise in the academic community, and Shanghai Chempartner will fully leverage its professional advantages to jointly develop therapeutic drugs.
Chempartner Pharmatech (300149.SZ): Possesses the capability of chemical design and synthesis, including peptides and small molecules.
Chempartner Pharmatech (300149.SZ) stated on the investor interaction platform on August 9th that the company has the ability to design and synthesize chemicals, including peptides and small molecules, as well as corresponding research and development capabilities such as drug screening models, which can help innovative drug customers, including weight loss drugs, to promote the development of related drugs.
Investors Don't See Light At End Of ChemPartner PharmaTech Co.,Ltd.'s (SZSE:300149) Tunnel
ChemPartner Pharmatech (300149.SZ): Currently, its wholly-owned subsidiary Hongyuan Pukang sells probiotics and probiotic products.
ChemPartner Pharmatech (300149.SZ) stated on its investor interaction platform on July 26 that the company's main business is pharmaceutical research and development and production services (CRO/CDMO), providing chemical and biological drug research and development and production services to global pharmaceutical companies, biotechnology companies and research institutions. According to the company's development strategy to focus on medical research and development and production service business (CRO/CDMO business), the company sold its probiotics (including fructo-oligosaccharides) business to the public in June 2022. Currently, its wholly-owned subsidiary, Hongyuan Pukang, sells probiotics and probiotic products.
ChemPartner Pharmatech (300149.SZ): As of June 4, the company had 24,470 shareholders.
ChemPartner Pharmatech (300149.SZ) stated on the investor interaction platform on June 6th that as of June 4th, the number of shareholders in the company was 24,470.
No Data